ARKUDA Therapeutics
Latest round
- Series B
Last raised
- Feb 2022
Total raised
- $108M
Investors
- 8
About ARKUDA Therapeutics
ARKUDA Therapeutics, Inc.Founded in 2018 and headquartered in Watertown, US, ARKUDA Therapeutics specializes in neurodegenerative disease therapeutics. The company operates independently and has not undergone any significant business pivots or changes in operations., Duane Burnett, and Gerhard Koenig, who serves as the CEO.ARKUDA Therapeutics focuses on developing innovative therapies aimed at addressing neurodegenerative diseases. The company’s core product offerings include a range of novel compounds designed to target the underlying mechanisms of diseases such as Alzheimer's and other forms of dementia. These therapies are engineered to enhance neuronal health and function, thereby aiming to slow disease progression and improve patient outcomes. ARKUDA's products are primarily directed toward healthcare providers, research institutions, and pharmaceutical partners, facilitating clinical trials and subsequent access to treatments for patients suffering from these conditions.ARKUDA Therapeutics generates revenue through strategic partnerships and collaborations with other biotech firms and academic institutions. Transactions involve upfront payments for licensing rights, followed by milestone payments linked to successful clinical development phases and potential royalties on future product sales. The company’s flagship products, still in various stages of clinical development, are positioned to leverage these partnerships, thereby enhancing their market entry strategies. The company aims to expand its offerings and enhance its product pipeline, with plans to penetrate additional markets in Europe by the end of 2023, particularly focusing on countries with high prevalence rates of neurodegenerative conditions.
Who invested in ARKUDA Therapeutics
8 investors across 2 rounds
See all investors in ARKUDA Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ARKUDA Therapeutics
Who invested in ARKUDA Therapeutics?
ARKUDA Therapeutics has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ARKUDA Therapeutics raised?
ARKUDA Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ARKUDA Therapeutics last raise money?
ARKUDA Therapeutics's most recent round on record is a Series B, in Feb 2022.
What does ARKUDA Therapeutics do?
ARKUDA Therapeutics is a biotechnology company.
Where is ARKUDA Therapeutics headquartered?
ARKUDA Therapeutics is headquartered in Watertown, US.
Which VCs invest in companies like ARKUDA Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ARKUDA Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like ARKUDA Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.